CSPC Pharmaceutical Group Limited (HKG: 1093) announced that data from the Phase I clinical study of SYS6002, a next‑generation Nectin‑4‑targeting antibody‑drug conjugate (ADC), as monotherapy for the treatment of previously treated advanced cervical cancer, have been presented as a rapid oral presentation at the 2026 Annual Global Meeting of the International Gynecologic Cancer Society (IGCS 2026) – with both dose cohorts demonstrating preliminary efficacy and a manageable safety profile after a median follow‑up of 16.1 months.
Regulatory Milestone
| Item | Detail |
|---|---|
| Presentation | Rapid oral presentation at IGCS 2026 Annual Global Meeting |
| Product | SYS6002 (Nectin‑4‑targeting ADC) |
| Study Phase | Phase I (safety, tolerability, PK, preliminary efficacy) |
| Indication | Previously treated advanced cervical cancer (monotherapy) |
| Enrollment | 82 patients across two dose cohorts |
| Median Follow‑Up | 16.1 months |
| Data Cutoff | 8 May 2026 |
| Phase III Status | Initiated – 2.4 mg/kg Q2W regimen in immunotherapy‑pretreated advanced cervical cancer (NCT07230626) |
Drug Profile & Mechanism of Action
- Molecule: SYS6002 – a next‑generation antibody‑drug conjugate (ADC)
- Target: Nectin‑4 – a cell‑adhesion molecule overexpressed in multiple solid tumors including cervical, urothelial, and breast cancers, with limited expression in normal adult tissues
- Payload: MMAE (monomethyl auristatin E) – a potent mitotic inhibitor that disrupts microtubule polymerization, inducing apoptosis in dividing cancer cells
- Conjugation Technology: Enzyme‑catalyzed site‑specific antibody conjugation – ensures precise, reproducible drug‑to‑antibody ratio (DAR), enhancing pharmacokinetic consistency and therapeutic index compared to stochastic conjugation methods
- Linker Design: Stable linker architecture that facilitates high‑concentration MMAE delivery to the tumor while reducing systemic toxin exposure, thereby improving the therapeutic window
- Differentiation vs. Existing Nectin‑4 ADCs: The site‑specific conjugation and stable linker are designed to address known safety limitations of earlier‑generation Nectin‑4 ADCs (notably skin toxicity and peripheral neuropathy), potentially enabling broader use and longer treatment duration
Clinical Evidence – Phase I Study (Monotherapy, Advanced Cervical Cancer)
Patient Population & Study Design
- Total Enrolled: 82 patients with advanced solid tumors; cervical cancer cohort data presented at IGCS 2026
- Cohort 1: 39 patients – 2.4 mg/kg once every 2 weeks (Q2W)
- Cohort 2: 43 patients – 3.6 mg/kg once every 3 weeks (Q3W)
- Median Follow‑Up: 16.1 months
- Setting: Previously treated advanced cervical cancer, monotherapy
Efficacy Results
| Endpoint | 2.4 mg/kg Q2W (n=39) | 3.6 mg/kg Q3W (n=43) |
|---|---|---|
| Confirmed ORR | 35.9 % | 28.6 % |
| Median DoR (confirmed responders) | 8.2 months | 10.3 months |
| Median PFS | 4.1 months | 4.3 months |
| Median OS | 15.1 months | 11.5 months |
Safety Profile
| Safety Parameter | Result |
|---|---|
| Overall AE Profile | Generally manageable; treatment‑related AEs mostly Grade 1–2 |
| Ocular‑Related AEs | Most common AE category; no Grade ≥ 3 events; no treatment discontinuations due to ocular AEs |
| Interstitial Lung Disease / Non‑Infectious Pneumonitis | Low incidence (2.4 %) |
| Treatment‑Related Rash | Any grade: 20.7 %; Grade ≥ 3: 1.2 %; no Stevens‑Johnson syndrome or toxic epidermal necrolysis |
| Peripheral Neuropathy | Low incidence (12.2 %); all Grade 1–2 |
| Treatment‑Related Deaths | None |
The safety profile demonstrates meaningful differentiation from earlier‑generation Nectin‑4 ADCs, which have been associated with higher rates of skin toxicity (including severe cutaneous adverse reactions) and peripheral neuropathy. The absence of Grade ≥ 3 ocular events, zero treatment discontinuations due to ocular AEs, and no cases of Stevens‑Johnson syndrome represent clinically significant safety advantages that could support broader patient eligibility and longer treatment duration.
Clinical Context – Advanced Cervical Cancer Landscape
| Treatment Line | Standard Options | Limitations |
|---|---|---|
| First‑Line | Chemotherapy + bevacizumab ± pembrolizumab (KEYNOTE‑826 regimen) | Progression inevitable; limited options after failure |
| Second‑Line+ | Tisotumab vedotin (ADC targeting tissue factor); chemotherapy; clinical trials | Modest efficacy; significant toxicity concerns |
| Post‑Immunotherapy | Very limited options – major unmet need | No established standard of care |
Cervical cancer remains a leading cause of cancer death in women globally, with an estimated 600,000+ new cases and 340,000+ deaths annually. Patients who progress after first‑line chemo‑immunotherapy face a particularly bleak prognosis with few approved therapeutic options. The 35.9% confirmed ORR and 15.1‑month median OS observed with SYS6002 2.4 mg/kg Q2W in a previously treated, immunotherapy‑pretreated population represent clinically meaningful signals that have propelled the program into Phase III registration‑enabling development.
Market Impact & Outlook
- Post‑Immunotherapy Cervical Cancer Gap: The rapid advancement of first‑line chemo‑immunotherapy has created a growing population of patients who progress after pembrolizumab‑containing regimens. SYS6002’s Phase III entry specifically targeting immunotherapy‑pretreated patients addresses this acute and expanding unmet need.
- Nectin‑4 ADC Competitive Landscape: The Nectin‑4 ADC class is anchored by enfortumab vedotin (Padcev, Astellas/Merck), approved in urothelial cancer, and tisotumab vedotin (Tivdak, Seagen/Genmab), approved in cervical cancer. SYS6002’s next‑generation conjugation technology and favorable safety profile (particularly the low rates of skin toxicity and neuropathy) position it as a potential best‑in‑class candidate if confirmed in Phase III.
- Phase III De‑Risking: The initiation of a Phase III trial (NCT07230626) for the 2.4 mg/kg Q2W regimen in immunotherapy‑pretreated advanced cervical cancer demonstrates CSPC’s confidence in the Phase I efficacy and safety signals, and accelerates the path toward potential regulatory filings.
- Platform Expansion Potential: Nectin‑4 is expressed across multiple tumor types (urothelial, breast, ovarian, head and neck), suggesting potential for indication expansion beyond cervical cancer – a strategic optionality that enhances the asset’s long‑term value.
- CSPC Pharmaceutical’s Oncology Pipeline: SYS6002 represents a key pillar in CSPC’s growing oncology ADC portfolio, complementing the company’s established capabilities in small‑molecule oncology and biologics manufacturing.
- Commercial Timeline: Phase III results, regulatory filing timelines, and partnership or licensing strategies Not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory trajectory, and commercial potential of SYS6002 in advanced cervical cancer and other indications. Phase I results do not guarantee Phase III success or marketing approval. Actual outcomes may differ due to risks including pivotal trial results, safety findings at larger scale, regulatory decisions, competitive dynamics, and the inherent uncertainties of ADC drug development.-Fineline Info & Tech
